Business Context and Reporting Period
Company: Upstream Bio, Inc. (Nasdaq: UPB)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Upstream Bio is a clinical-stage biopharmaceutical company developing verekitug, a monoclonal antibody targeting the Thymic Stromal Lymphopoietin (TSLP) receptor. The company is advancing verekitug in Phase 2 trials for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Collaboration Revenue | $1,807 | $1,503 | $773 |
| Total Operating Expenses | $87,790 | $77,863 | $43,141 |
| Net Loss | $(80,293) | $(67,236) | $(39,702) |
| Net Loss Per Share (Basic & Diluted) | $(1.47) | $(1.25) | $(0.73) |
| Cash, Cash Equivalents & Short-Term Investments | $261,300 | $341,509 | $261,300 |
| Accumulated Deficit | $(414,516) | $(334,223) | $(414,516) |
| Net Cash Used in Operating Activities | $(83,473) | $(80,404) | N/A |
Note: Short-term investments decreased from $239.9 million at Dec 31, 2025 to $181.9 million at June 30, 2026. Cash and cash equivalents decreased from $101.6 million to $79.4 million.
Material Changes vs. Prior Period
- Revenue: Collaboration revenue increased by $304,000 (20%) for the six months ended June 30, 2026, compared to the prior year period. This revenue is derived from cost reimbursements under the Maruho License Agreement for research and development activities in Japan.
- Operating Expenses: Total operating expenses increased by $9.9 million (13%) year-over-year.
- R&D Expenses: Increased by $9.0 million to $72.7 million. The increase was driven by higher direct costs for the COPD indication ($6.8 million increase) and increased personnel expenses ($5.9 million increase), partially offset by a decrease in manufacturing costs ($3.1 million decrease).
- G&A Expenses: Increased by $0.9 million to $15.1 million, primarily due to higher personnel expenses.
- Net Loss: Net loss increased by $13.1 million to $80.3 million for the six-month period, reflecting the increase in operating expenses which outpaced the growth in collaboration revenue and interest income.
- Interest Income: Decreased by $3.5 million to $5.7 million due to lower balances in short-term investments.
Guidance, Outlook, and Risks
- Clinical Outlook: The company reported positive top-line results for severe asthma (February 2026) and CRSwNP (September 2025). Enrollment for the Phase 2 COPD trial is complete, with data expected in the second half of 2027. The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in the first quarter of 2027.
- Liquidity: As of June 30, 2026, the company held $261.3 million in cash, cash equivalents, and short-term investments. Management believes these resources are sufficient to fund operations through 2027. The company maintains an "at-the-market" (ATM) offering program with up to $150.0 million available; $2.1 million in net proceeds were generated under this program in the first half of 2026.
- Risks:
- Capital Needs: The company expects to continue incurring significant losses and will require additional financing to support operations beyond 2027. Failure to raise capital could force delays or reductions in development programs.
- Manufacturing & Supply Chain: The company relies on third-party manufacturers, including WuXi Biologics. Risks include potential designation of suppliers under the BIOSECURE Act, which could disrupt supply chains.
- Regulatory & Clinical: Success depends on the ability to replicate positive Phase 2 results in Phase 3 trials and obtain regulatory approval. There is no guarantee of approval or commercial success.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $261.3 million cash balance to fund the planned Phase 3 trials in 2027 and subsequent commercialization efforts.
- ATM Program Utilization: Monitor the pace of share sales under the $150 million ATM program and the resulting dilution to existing shareholders.
- Manufacturing Dependencies: Assess the impact of the BIOSECURE Act and potential restrictions on WuXi Biologics on the company's ability to secure clinical and commercial supplies.
- Clinical Milestones: Track the initiation of Phase 3 trials in Q1 2027 and the release of Phase 2 COPD data in H2 2027.
- Collaboration Revenue: Confirm the sustainability of revenue from the Maruho agreement, which is based on reimbursable R&D costs rather than product sales.